| Phase 3 |
| NCT07270991 |
Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic… |
Metastatic Oesogastric Adenocarcinoma |
Recruiting |
2026-02-05 |
| NCT06207981 |
Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared… |
Anal Cancer |
Recruiting |
2025-09-02 |
| NCT02885753 |
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan… |
Colorectal Neoplasms |
Recruiting |
2025-07-09 |
| Phase 2 |
| NCT05706779 |
Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation… |
Colorectal Cancer |
Recruiting |
2025-09-02 |
| NCT07616362 |
Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With… |
Borderline Resectable Pancreatic Ductal Adenocarcinoma |
Not Yet Recruiting |
2026-06-11 |
| NCT07150403 |
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet… |
Metastatic Colorectal Carcinoma (mCRC) |
Not Yet Recruiting |
2025-09-08 |
| NCT07128290 |
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic… |
Intrahepatic Cholangiocarcinoma (Icc) |
Not Yet Recruiting |
2025-08-17 |
| NCT07124884 |
5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in… |
Colorectal Carcinoma |
Not Yet Recruiting |
2025-08-15 |
| Not applicable |
| NCT07124858 |
Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib… |
Metastatic Colorectal Cancer (CRC) |
Recruiting |
2026-05-26 |
| Not specified |
| NCT06353854 |
Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to… |
Colorectal Cancer Metastatic |
Recruiting |
2025-10-06 |
| NCT06541652 |
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers |
Hepatocholangiocarcinoma |
Recruiting |
2025-08-05 |
| NCT05511688 |
National Cohort of Colorectal Cancers With Microsatellite Instability |
Colorectal Cancer |
Active, Not Recruiting |
2025-09-02 |